SVP Liquidates All Direct Holdings in Supernus Pharmaceuticals
Summary
Supernus Pharmaceuticals' SVP of Commercial Operations, William Todd Horich, sold all of his direct shares, totaling $672,889, indicating a complete liquidation of his direct stake.
Key Events
-
SVP Liquidates Direct Holdings
William Todd Horich, SVP of Commercial Operations, disposed of all 8,877 shares of common stock through open market sales and 3,455 shares for tax withholding, resulting in zero direct shares held post-transaction.
-
Significant Insider Selling
The total value of shares sold by the SVP amounted to $672,889, comprising $483,797 from open market sales and $189,092 from tax-related dispositions.
-
Contributes to Broader Insider Distribution
This transaction follows a pattern of insider selling at Supernus Pharmaceuticals, with net insider sales of over $1.3 million from three active insiders in the last 90 days.
Analysis
William Todd Horich, SVP of Commercial Operations, has fully divested his direct holdings in Supernus Pharmaceuticals through open market sales and tax withholdings. While the total transaction value is modest relative to the company's market capitalization, a complete liquidation by a senior officer typically signals a lack of confidence in the company's future prospects. This transaction contributes to a broader pattern of insider distribution observed over the last 90 days.
At the time of this filing, SUPN was trading at $53.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $29.16 to $59.68. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.